649P - Expression of CXCR4 in tumor and bone marrow of gastric cancer patients: association with hypoxia-regulated indices, disseminated tumor cells and s...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Gastric Cancer
Pathology/Molecular Biology
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Dmitry Osinsky
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors D. Osinsky1, A. Kovelskaya2, L. Bubnovskaya2, I. Ganusevich2, L. Gumenyuk2, S. Merentsev1, S. Osinsky2, L. Mamontova2
  • 1Abdominal Oncology, Kiev's City Clinical Oncological Centre, 03115 - Kiev/UA
  • 2Dept. Of Microenvironment Of Tumor Cells, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Natl. Acad. of Sci. of Ukraine, Kiev, Ukraine, Kiev/UA



CXCR4 expression is associated with metastasis and poor outcome of various cancers but its role in gastric cancer (GC) is still unclear. This study was aimed to analyze the association of CXCR4 expression in GC and bone marrow (BM) with clinical outcome.


65 resected tumor specimens were studied. Immunohistochemistry, NMR-spectroscopy, and zymography were used. Disseminated tumors cells (DTCs) in BM was detected by immunocytochemistry. All patients were thoroughly informed about the study. Statistical analyses were done using NCSS2000/PASS2000 and Prism (version 4.03) software packages.


CXCR4 protein was expressed in 78.5% of GC specimens. It was correlated with level of tumor hypoxia (assessed by PME/Pi ratio; r = 0.492, p < 0.05), VEGF expression (r = 0.337, p < 0.01) and gelatinases activity (r = 0.33; p < 0.05). CXCR4+ cells in GC was detected in 80% of patients with DTC in BM. Overall survival (OS) of patients with CXCR4+-tumors was poorer than that of patients with CXCR4-tumors (p < 0.037). The CXCR4+ cells in BM was found in 46% of all patients, and in 56% of patients with DTC. It was also detected that CXCR4+ cells in BM in patients with M0 category was detected in 63% of patients with DTC. CXCR4 expression in BM was not associated with OS. It was evaluated that in all patients with CXCR+ tumors risk of unfavorable outcome increased by more a factor of 2.82 (HR = 2.82; 95%CI 1.162–6.832; p < 0.05). CXCR4 expression in BM was positively associated with DTC, especially in patients with M0 category. It was observed that in patients both with M0 category and CXCR4+ BM risk of unfavorable outcome increased by a factor of 3.4 (HR = 3.4; 95%CI 1.156–12.054; p < 0.03).


CXCR4 expression in tumor was positively correlated with hypoxia and VEGF expression in tumor and OS. CXCR4 expression in BM is associated with DTC.


All authors have declared no conflicts of interest.